Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID-19 and its effect on the clinical landscape.
Rare disease drug development varies from the pathways seen in more established indications. The sample sizes are often...
Pharm-Olam is committed to following our industry’s best practices – sometimes even those from other segments of our industry....
Tags: Data Management
Systemic lupus erythematosus is an autoimmune disease that presents differently in each person. There are roughly 150 people...
Tags: Pharm-Olam Insights, Autoimmune
The COVID Pandemic is continuing to evolve. Governments and companies around the world are striving to develop vaccines and...
Earlier this year, Pharm-Olam partnered with Informa’s Pharma Intelligence to draft a white paper that discusses the...
Tags: Infectious Disease & Vaccines, COVID-19, Global Coverage
The COVID-19 Pandemic continues to evolve and fluctuate across the globe – but not evenly or predictably. Some countries have...
Tags: Pharm-Olam Insights, Infectious Disease & Vaccines, Investigator Insights,
In rare disease, every patient matters and it is important for CRO and sponsor medical staff to effectively monitor and...
The United Kingdom officially withdrew from the European Union (EU) on Jan 31, 2020. They have until Dec 31, 2020 to complete...
Subscribe to our blog and we'll give you our GDPR Controller & Processor Checklist.
